Drug intelligence / Profile preview

CB303

Development stage: Unknown
Lead developer: CentricsBio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CB303 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed by CentricsBio for the treatment of solid tumors. The therapy is designed to target CD300c (also known as CMRF35-like molecule 6 or CB301 antigen), a novel immune checkpoint and cancer antigen expressed on the surface of various solid tumor cells. By targeting CD300c, CB303 aims to overcome the immunosuppressive microenvironment characteristic of solid tumors, activate T cells, and directly eliminate cancer cells. CB303 is currently in Phase 1 clinical development.

Targets

CD300c (CD300 antigen-like family member C)

Beyond the preview

Go deeper on CB303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB303.

Explore the full profile